Ovarian Cancer Clinical Trials & Research

Doctors at Memorial Sloan Kettering are constantly working to improve treatment for ovarian cancer through clinical trials. Participating in a clinical trial may give you access to treatments that are not widely available elsewhere, and may offer additional options if your cancer has returned after standard treatment.

Our doctors lead clinical trials that test new drugs and drug combinations, surgical approaches, and strategies for preserving quality of life during and after treatment. We can help determine which clinical trials are right for you.

The following clinical trials for ovarian cancer are currently enrolling new patients. To learn more about a particular study, choose from the list below.

and/or
27 Clinical Trials found
A Phase 3 Study of Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Researchers are assessing maintenance therapy with olaparib given for 1 or 2 years, with or without bevacizumab, to treat ovarian cancer. The people in this study have stage 3 or 4 ovarian cancer with certain genetic mutations (changes).
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase I/II Study of MORAb-202 in People with Endometrial or Ovarian Cancer
The purpose of this study is to assess the safety and effectiveness of the investigational drug MORAb-202 in people with endometrial or ovarian cancer. MORAb-202 targets a protein called FRA on cancer cells and delivers eribulin (a chemotherapy drug) directly to these cells, which may slow or stop cancer growth. MORAb-202 is given intravenously (by vein).
New York City
A Phase I/II Study of REGN4018 Given Alone or in Combination with Cemiplimab in Women with Recurrent Ovarian Cancer
The purpose of this study is to assess the safety of the investigational treatment REGN4018 alone and in combination with cemiplimab in women with ovarian, peritoneal, or fallopian tube cancer that has come back or gotten worse after previous treatment. REGN4018 is a type of drug called a bispecific antibody: it binds to two specific proteins (MUC16 and CD3) that may be involved in the growth and survival of cancer.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase I/II Study of REGN5668 plus Cemiplimab or REGN4018 in People with Recurrent Ovarian Cancer
Researchers are doing this study to find out whether giving the investigational drug REGN5668 with cemiplimab immunotherapy or with REGN4018 is a safe treatment for people with ovarian, peritoneal, or fallopian tube cancer. They will also try to find the highest dose of REGN5668 that can be given safely with cemiplimab or with REGN4018.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase II Study of Trastuzumab Deruxtecan in People with HER2-Positive Solid Tumors
The purpose of this study is to assess the safety and effectiveness of the drug trastuzumab deruxtecan (also known as DS-8201A) in patients with inoperable or metastatic solid tumors that produce too much of a protein called HER2, including biliary tract, bladder, cervical, endometrial, ovarian, and pancreatic cancers.
New York City, Westchester, Monmouth
A Study of SLV-154 in People With Solid Tumor Cancer
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
Study of Isoquercetin in People With Ovarian Cancer
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau